Paratek Pharmaceuticals (PRTK) Reaches New 12-Month Low At $5.63

By Daily Independent

Shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $5.63 and last traded at $5.76, with a volume of 432617 shares trading hands. The stock had previously closed at $5.84.

PRTK has been the subject of several analyst reports. Bank of America initiated coverage on shares of Paratek Pharmaceuticals in a research report on Monday, August 27th. They set a neutral rating and a $13.00 price target for the company. ValuEngine upgraded shares of Paratek Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, October 2nd. Guggenheim set a $26.00 target price on shares of Paratek Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, October 3rd. BidaskClub upgraded shares of Paratek Pharmaceuticals from a strong sell rating to a sell rating in a report on Saturday, October 6th. Finally, HC Wainwright dropped their target price on shares of Paratek Pharmaceuticals from $55.00 to $22.00 and set a buy rating for the company in a report on Friday, November 23rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of Buy and an average price target of $24.63.

The company has a market cap of $186.74 million, a price-to-earnings ratio of -1.75 and a beta of 0.76. The company has a current ratio of 11.39, a quick ratio of 11.39 and a debt-to-equity ratio of 3.97.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the Zacks consensus estimate of ($0.85) by ($0.16). Paratek Pharmaceuticals had a negative net margin of 2,155.03% and a negative return on equity of 132.55%. The business had revenue of $0.05 million for the quarter, compared to the consensus estimate of $5.89 million. Equities analysts predict that Paratek Pharmaceuticals Inc will post -3.47 earnings per share for the current fiscal year.

In related news, Chairman Michael Bigham sold 16,313 shares of the firms stock in a transaction that occurred on Wednesday, October 3rd. The shares were sold at an average price of $9.82, for a total transaction of $160,193.66. Following the completion of the sale, the chairman now owns 213,480 shares of the companys stock, valued at $2,096,373.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Evan Loh sold 11,525 shares of the firms stock in a transaction that occurred on Thursday, December 13th. The shares were sold at an average price of $6.50, for a total transaction of $74,912.50. Following the sale, the chief operating officer now directly owns 283,700 shares of the companys stock, valued at approximately $1,844,050. The disclosure for this sale can be found here. Insiders have sold 85,421 shares of company stock valued at $738,227 in the last ninety days. Insiders own 6.20% of the companys stock.

Several institutional investors and hedge funds have recently made changes to their positions in PRTK. Highland Capital Management LP increased its position in shares of Paratek Pharmaceuticals by 99.9% during the second quarter. Highland Capital Management LP now owns 1,917,878 shares of the specialty pharmaceutical companys stock valued at $19,562,000 after acquiring an additional 958,600 shares in the last quarter. BlackRock Inc. increased its position in shares of Paratek Pharmaceuticals by 27.3% during the second quarter. BlackRock Inc. now owns 2,583,390 shares of the specialty pharmaceutical companys stock valued at $26,350,000 after acquiring an additional 554,545 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Paratek Pharmaceuticals during the third quarter valued at approximately $1,860,000. Granahan Investment Management Inc. MA bought a new stake in shares of Paratek Pharmaceuticals during the second quarter valued at approximately $1,801,000. Finally, Water Island Capital LLC increased its position in shares of Paratek Pharmaceuticals by 53.5% during the third quarter. Water Island Capital LLC now owns 439,726 shares of the specialty pharmaceutical companys stock valued at $4,265,000 after acquiring an additional 153,226 shares in the last quarter. 74.75% of the stock is owned by institutional investors.

This article provided by NewsEdge.